About Aktis Oncology Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.aktisoncology.com/
Frequently Asked Questions
What is the 52-week range for AKTS?
The 52-week high is $34.1899 and the 52-week low is $14.72.
What is the P/E ratio for AKTS?
The P/E ratio data is currently unavailable.
What is the dividend yield for AKTS?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -30.80%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -810.19%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 5.88.
Analyst Recommendation Trends
Wall Street analyst consensus for AKTS over the last few months:
Latest AKTS News
Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target
Wedbush analyst David Nierengarten reiterates Aktis Oncology (NASDAQ:AKTS) with a Outperform and maintains $35 price target.
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumorsEnrollment is ongoing in the Phase 1b BActinium-1 clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); preliminary data expected in 2027 BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potentia
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519
Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumorsEnrollment is ongoing in the Phase 1b BActinium-1 clinical trial of
Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Aktis Oncology, Inc. (AKTS) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 8:30 AM EDTCompany ParticipantsMatthew Roden -...
Aktis Oncology to Present at Upcoming September Investor Conferences
BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will participate in the following investor conferences in September. Morgan Stanley 24th Annual Global Healthcare C
Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40
Oppenheimer analyst Jeff Jones initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $40.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-23 | Czibere Akos | -12,500 | - | - |
| 2026-09-23 | Czibere Akos | -7,401 | $21.0307 | $155,648 |
| 2026-09-23 | Czibere Akos | -5,099 | $20.1947 | $102,973 |
| 2026-09-23 | Czibere Akos | +12,500 | $4.95 | $61,875 |
| 2026-07-20 | Herrmann Ken | -1,350 | - | - |
| 2026-07-20 | Herrmann Ken | -3,506 | - | - |
| 2026-07-20 | Herrmann Ken | -1,350 | $24.5622 | $33,159 |
| 2026-07-20 | Herrmann Ken | -3,506 | $24.5622 | $86,115 |
| 2026-07-20 | Herrmann Ken | +1,350 | $1.91 | $2,579 |
| 2026-07-20 | Herrmann Ken | +3,506 | $0.08 | $280 |
| 2026-07-17 | Herrmann Ken | -3,065 | - | - |
| 2026-07-17 | Herrmann Ken | -3,065 | $25.2067 | $77,259 |
| 2026-07-17 | Herrmann Ken | +3,065 | $0.08 | $245 |
| 2026-07-08 | Ron-Bigger Shulamit | -50,000 | - | - |
| 2026-07-08 | Ron-Bigger Shulamit | -4,200 | $28.7476 | $120,740 |
| 2026-07-08 | Ron-Bigger Shulamit | -30,000 | $27.9379 | $838,137 |
| 2026-07-08 | Ron-Bigger Shulamit | -15,800 | $27.1317 | $428,681 |
| 2026-07-08 | Ron-Bigger Shulamit | +50,000 | $3.66 | $183,000 |
| 2026-07-08 | Czibere Akos | -50,000 | - | - |
| 2026-07-08 | Czibere Akos | -4,371 | $28.7078 | $125,482 |
| 2026-07-08 | Czibere Akos | -30,829 | $27.9521 | $861,735 |
| 2026-07-08 | Czibere Akos | -14,800 | $27.1273 | $401,484 |
| 2026-07-08 | Czibere Akos | +50,000 | $4.95 | $247,500 |
| 2026-04-15 | Gormley Glenn | +37,866 | - | - |
| 2026-01-12 | Foley Todd | -2,727,273 | - | - |
| 2026-01-12 | Foley Todd | -10,227,273 | - | - |
| 2026-01-12 | Foley Todd | -2,272,727 | - | - |
| 2026-01-12 | Foley Todd | +232,870 | $18 | $4,191,660 |
| 2026-01-12 | Foley Todd | +716,872 | - | - |
| 2026-01-12 | Foley Todd | +2,688,270 | - | - |
| 2026-01-12 | Foley Todd | +597,391 | - | - |
| 2026-01-12 | EVNIN LUKE | -6,000,000 | - | - |
| 2026-01-12 | EVNIN LUKE | -22,500,000 | - | - |
| 2026-01-12 | EVNIN LUKE | -5,000,000 | - | - |
| 2026-01-12 | EVNIN LUKE | +1,112,777 | $18 | $20,029,986 |
| 2026-01-12 | EVNIN LUKE | +1,577,119 | - | - |
| 2026-01-12 | EVNIN LUKE | +5,914,197 | - | - |
| 2026-01-12 | EVNIN LUKE | +1,314,262 | - | - |
| 2026-01-12 | GADICKE ANSBERT | -6,000,000 | - | - |
| 2026-01-12 | GADICKE ANSBERT | -22,500,000 | - | - |
| 2026-01-12 | GADICKE ANSBERT | -5,000,000 | - | - |
| 2026-01-12 | GADICKE ANSBERT | +1,112,777 | $18 | $20,029,986 |
| 2026-01-12 | GADICKE ANSBERT | +1,577,119 | - | - |
| 2026-01-12 | GADICKE ANSBERT | +5,914,197 | - | - |
| 2026-01-12 | GADICKE ANSBERT | +1,314,262 | - | - |
| 2026-01-12 | Vida Ventures II, LLC | -101,250 | - | - |
| 2026-01-12 | Vida Ventures II, LLC | -3,648,750 | - | - |
| 2026-01-12 | Vida Ventures II, LLC | -411,750 | - | - |
| 2026-01-12 | Vida Ventures II, LLC | -14,838,250 | - | - |
| 2026-01-12 | Vida Ventures II, LLC | +22,545 | $18 | $405,810 |
| 2026-01-12 | Vida Ventures II, LLC | +134,842 | - | - |
| 2026-01-12 | Vida Ventures II, LLC | +812,455 | $18 | $14,624,190 |
| 2026-01-12 | Vida Ventures II, LLC | +4,859,370 | - | - |
| 2026-01-12 | Segal Lloyd Mitchell | -24,687 | - | - |
| 2026-01-12 | Segal Lloyd Mitchell | -50,000 | - | - |
| 2026-01-12 | Segal Lloyd Mitchell | +19,631 | - | - |
| 2026-01-12 | NODELMAN OLEG | +86,222 | - | - |
| 2026-01-12 | NODELMAN OLEG | +965,190 | - | - |
| 2026-01-12 | NODELMAN OLEG | -102,500 | - | - |
| 2026-01-12 | NODELMAN OLEG | -2,397,500 | - | - |
| 2026-01-12 | NODELMAN OLEG | -488,891 | - | - |
| 2026-01-12 | NODELMAN OLEG | -997,299 | - | - |
| 2026-01-12 | NODELMAN OLEG | -9,913,810 | - | - |
| 2026-01-12 | NODELMAN OLEG | +144,443 | $18 | $2,599,974 |
| 2026-01-12 | NODELMAN OLEG | +2,077,779 | $18 | $37,400,022 |
| 2026-01-12 | NODELMAN OLEG | +128,506 | - | - |
| 2026-01-12 | NODELMAN OLEG | +202,862 | - | - |
| 2026-01-12 | NODELMAN OLEG | +2,270,879 | - | - |
| 2026-01-12 | Kim Helen Susan | -101,250 | - | - |
| 2026-01-12 | Kim Helen Susan | -3,648,750 | - | - |
| 2026-01-12 | Kim Helen Susan | -411,750 | - | - |
| 2026-01-12 | Kim Helen Susan | -14,838,250 | - | - |
| 2026-01-12 | Kim Helen Susan | +22,545 | $18 | $405,810 |
| 2026-01-12 | Kim Helen Susan | +134,842 | - | - |
| 2026-01-12 | Kim Helen Susan | +812,455 | $18 | $14,624,190 |
| 2026-01-12 | Kim Helen Susan | +4,859,370 | - | - |